ImmunityBio, Inc. 8-K

What Happened
On April 6, 2026, ImmunityBio, Inc. announced via press release that it submitted a comprehensive response to a Warning Letter issued by the U.S. Food and Drug Administration Office of Prescription Drug Promotion (OPDP) on March 13, 2026. The company said the response outlines immediate and planned corrective actions. The press release was furnished as Exhibit 99.1 to the Form 8‑K under Item 7.01 (Regulation FD Disclosure).

Key Details

• Warning Letter issued by FDA OPDP: March 13, 2026.
• ImmunityBio press release and 8‑K filing date: April 6, 2026.
• Company action: submitted a comprehensive response and outlined immediate and planned corrective actions.
• Exhibit furnished: Press Release dated April 6, 2026 (Exhibit 99.1).

Why It Matters
This disclosure relates to regulatory compliance and the company’s promotional communications—areas that can affect corporate reputation and regulatory risk. For investors, the filing confirms ImmunityBio has formally responded to FDA concerns and described steps it intends to take; investors should watch for further FDA correspondence or additional company updates that could affect operations, marketing practices, or risk profile.